share_log

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Edwards Larry Todd

SEC ·  Oct 4 04:56

Summary by Futu AI

Larry Todd Edwards, the Senior Vice President and Chief Commercial Officer of Arcutis Biotherapeutics, completed a sale of company stock on October 2, 2024. The transaction involved the disposal of 3,725 shares of common stock at a price of $10.0122 per share, resulting in a total sale value of $37,295.45. Following the sale, Edwards holds a total of 136,635 shares in the company. The sale was conducted in the open market, reflecting a direct ownership transaction.
Larry Todd Edwards, the Senior Vice President and Chief Commercial Officer of Arcutis Biotherapeutics, completed a sale of company stock on October 2, 2024. The transaction involved the disposal of 3,725 shares of common stock at a price of $10.0122 per share, resulting in a total sale value of $37,295.45. Following the sale, Edwards holds a total of 136,635 shares in the company. The sale was conducted in the open market, reflecting a direct ownership transaction.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Related Stocks Related Stocks
    Symbol Mini Chart Latest Price
    Vor Biopharma
    VOR
    -- 1.270
    Abpro Holdings
    ABP
    -- 4.490
    Galectin Therapeutics
    GALT
    -- 1.150
    Aptorum
    APM
    -- 1.0800
    Evaxion Biotech
    EVAX
    -- 1.060

    Unlock the Full List